Clinical Trial Update: Lovenox 30 mg Twice Daily (BID) Versus 40 mg Once Daily (QD) [Phase 4]

View source ↗

Summary

Phase 4 clinical trial comparing Lovenox 30 mg twice daily versus 40 mg once daily in trauma/surgery patients, currently recruiting.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Deep Vein Thrombosis
• Surgery
• Thromboembolic Events
• Trauma

Drugs mentioned

• Lovenox (enoxaparin)

Snippet

Sponsor: Oregon Health and Science University | Conditions: Trauma, Surgery | Phase 4 | Status: RECRUITING